Protocol for a randomized control trial of the Building Regulation in Dual Generations Program (BRIDGE): preventing the intergenerational transmission of mental illness in at-risk preschool children.

Protocol for a randomized control trial of the Building Regulation in Dual Generations Program (BRIDGE): preventing the intergenerational transmission of mental illness in at-risk preschool children.

Publication date: Sep 19, 2023

Since the onset of the COVID-19 pandemic, the worldwide prevalence of maternal depression has risen sharply; it is now estimated that one quarter of mothers experience clinically significant depression symptoms. Exposure to maternal depression during early childhood increases the risk for the development of childhood mental illness (MI) in offspring, with altered parenting practices mediating the association between maternal depression and child outcomes. Dual-generation interventions, which aim to simultaneously treat parent and child mental health, show promise for improving outcomes for mothers with depression and their young children. The Building Regulation in Dual Generations (BRIDGE) program combines Dialectical Behavior Therapy (DBT) and parenting skills training to concurrently treat maternal depression and improve parenting practices. In pilot within-group studies, BRIDGE has led to large reductions in maternal depression and child MI symptoms. The aim of the current study is to evaluate the efficacy of BRIDGE in reducing maternal depression and child MI symptoms (primary outcomes) as well as parenting stress and harsh parenting (secondary outcomes). A three-armed randomized control trial with equal group sizes will be conducted to compare the efficacy of (1) BRIDGE (DBT + parenting skills), (2) DBT skills training, and (3) services-as-usual. Participants (n = 180) will be mothers of 3- to 5-year-old children who report elevated depression symptoms. Those randomized to BRIDGE or DBT skills training will complete a 16-week group therapy intervention. Assessments will be administered at pre-intervention(T1) post-intervention (T2), and 6-month follow-up (T3). Dual-generation programs offer an innovative approach to prevent the intergenerational transmission of mental illness. The current study will add to the evidence base for BRIDGE by comparing it to a stand-alone mental health intervention and a services-as-usual group. These comparisons will provide valuable information on the relative efficacy of including parenting support in a mental health intervention for parents. The results will contribute to our understanding of how maternal depression affects children’s development and how intervening at both a mental health and parenting level may affect child and family outcomes. Name of registry: Clinical Trials Protocol Registration and Results System; trial registration number: NCT05959538; date of registry: July 24, 2023; available: https://classic. gov/ct2/show/NCT05959538.

Open Access PDF

Concepts Keywords
July Child mental illness
Nct05959538 Dialectical behavior therapy
Pandemic Maternal depression
Preschool Parent skills training
Therapy Randomized controlled trial

Semantics

Type Source Name
disease VO protocol
disease MESH mental illness
disease MESH COVID-19 pandemic
drug DRUGBANK Aspartame
disease VO report
disease IDO intervention
pathway REACTOME Reproduction
disease MESH mood disorders
drug DRUGBANK Trestolone
disease IDO quality
disease MESH obsession
disease MESH uncertainty
disease VO effective
disease VO Canada
drug DRUGBANK Coenzyme M
drug DRUGBANK Serine
disease MESH suicide
disease MESH post traumatic stress disorder
drug DRUGBANK Ethanol
disease MESH psychotic disorder
disease MESH dissociation
disease MESH substance dependence
disease IDO process
disease VO effectiveness
disease VO Imovax ID
disease IDO disposition
disease VO time
disease VO monthly
disease VO URE
disease IDO symptom
disease VO ineffective
disease MESH Anxiety Disorder
drug DRUGBANK Medical Cannabis
disease MESH marital status
disease IDO history
drug DRUGBANK Methylergometrine
drug DRUGBANK Esomeprazole
disease IDO production
disease VO document
disease VO adverse event
disease MESH psychological distress
disease VO frequency
disease VO USA
disease MESH disruptive behavior
disease VO population
drug DRUGBANK Tropicamide
disease MESH violence
disease MESH schizophrenia
disease MESH bipolar disorder
disease MESH major depressive disorder
disease MESH treatment resistant depression
disease MESH Postpartum depression
disease VO efficiency
drug DRUGBANK Gold
disease MESH fibromyalgia
disease MESH Alcoholism
pathway KEGG Alcoholism

Original Article

(Visited 1 times, 1 visits today)